The stimulation of food intake by selective agonists of mu, kappa and delta opioid receptors

Inhibition of drinking by naltrexone in the rat: interaction with the dopamine D-1 antagonist SCH 23390 and the D-2 antagonist sulpiride

The involvement of dopamine receptors in water intake was investigated in the rat deprived of water for 24 hr. A 0.03 mg/kg dose of SCH 23390 markedly enhanced naltrexone (0.1 and 10.0 mg/kg)-induced hypodipsia, whilst the drug alone significantly decreased water intake at doses of 0.01 to 3.0 mg/kg, accompanied by marked motor dysfunction. Sulpiride (20.0 and 40.0 mg/kg) did not markedly affect water intake and naltrexone-induced hypodipsia. Consistent with previous results, apomorphine (0.3 mg/kg) alone was without marked effects, while it produced a marked potentiation of naltrexone (1.0 and 10.0 mg/kg)-induced hypodipsia. SCH 23390 (0.003 mg/kg) and sulpiride (40.0 mg/kg) completely antagonized the enhancing effects of apomorphine on naltrexone-induced hypodipsia. Similar effects were also seen in the latency to begin drinking. In contrast to the effects on naltrexone-induced hypodipsia, it appears that both dopamine D-1 and D-2 receptors play a key role in the effects of apomorphine on naltrexone-induced hypodipsia in the rat.

Dynorphin A (1-13), microinjected into the preoptic area, stimulates water intake in rats

The effects of dynorphin A (1-13) (DYN), injected into the preoptic area, was investigated on water intake in rats. DYN at both doses of 2 and 10 nmoles significantly increased water intake for two and four hours after the injection in a dose related fashion. However, no significant change was observed in food intake. Naloxone pretreatment (0.3 mg/kg, s.c.) completely attenuated the DYN-induced stimulation of water intake. The present studies suggest that DYN in the preoptic area may play an important role in the regulation of drinking behavior, but have no effect on food intake.

Effects of streptozotocin-induced diabetes on feeding stimulated by centrally administered opioid agonists

The potencies of several opioid agonists are reduced in diabetic animals and in animals made hyperglycemic via injections of glucose. In this report we examined the effects of streptozotocin-induced diabetes on the feeding responses to centrally administered opioid agonists with differing receptor selectivities. The selective mu receptor agonist Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAGO) caused a larger increase in intake in diabetic rats than in controls. In both groups feeding responses were greater on the fourth day of daily injections than on the first day. The delta receptor agonist [D-Ser2,Leu5]-enkephalin-Thr6 (DSLET) stimulated intake in controls but not in diabetics. However, the elevated baseline and large variability in intake of the diabetics in this experiment prevent drawing a conclusion on diabetes-induced changes in the potency of this peptide. No differences between controls and diabetics were apparent in the feeding responses to U50, 488H, a selective kappa receptor agonist. These data suggest that diabetes may differentially affect the classes of opioid receptors or the binding of ligands to these receptors.

Multiple brain sites sensitive to feeding stimulation by opioid agonists: a cannula-mapping study

Evidence suggests that brain opioid receptors of the mu, delta and kappa subtypes may be involved in the control of feeding behavior. However, limited information is available regarding the specific anatomical location of these feeding relevant opioid receptors. To address this problem, we microinjected three opioid agonists, morphine, (D-Ala2)-Met-enkephalinamide (DALA) or MR 2034, into one of 15 different brain areas and measured the subsequent feeding responses of satiated rats. Morphine (25 nmol) and DALA (6.8 nmol) both elicited strong feeding responses from the same five brain areas, namely, the paraventricular, dorsomedial and lateral hypothalamus, as well as from sites within the septum and amygdala. No other brain sites yielded significant responses to these opioid receptor agonists. In contrast to this anatomically specific pattern of effects, the opioid agonist MR 2034 (8.6 nmol) produced a feeding response which was generally smaller in magnitude and had little anatomical specificity. These findings suggest that opioid receptor systems for stimulating feeding exist in multiple discrete brain areas. Of the regions tested, specific sites within the hypothalamus, septum and amygdala are distinguished as being most sensitive to feeding stimulation by morphine and DALA.

The opioid antagonist, MR2266, specifically decreases saline intake in the mouse

The effects of the opioid antagonist, Mr2266 [(-)-(1R,5R,9R)-5,9-diethyl-2-(3-furyl-methyl)-2'-hydroxy-6,7-benzomo rph an] on the intake of water and saline (0.9%) were investigated in the mouse, deprived of water for 24 hr. In an attempt to evaluate motor functions, the behavior after treatment with Mr2266 was also examined by using multi-dimensional behavioral analyses. Although smaller doses (1.0, 3.0 and 10.0 mg/kg) of Mr2266 failed to affect significantly the intake of water, a larger dose (30.0 mg/kg) elicited a significant attenuation in the intake of water. During a 30 min observation, Mr2266 (30.0 mg/kg) depressed markedly linear locomotion, while other behavioral responses, such as rearing and grooming, remained unchanged. In contrast, 1.0-30.0 mg/kg doses of the drug produced a significant reduction in the intake of saline. The drug Mr2266 had no significant effects on the latency to start drinking at any doses tested. These results suggest that Mr2266 specifically blocks the intake of saline of the mouse through the mediation of opioid systems.

Effects of intrahypothalamic administration of opioid peptides selective for mu-, kappa, and delta-receptors on different schedules of water intake in the rat

The effects of opioid peptides selective for mu, kappa, and delta-opioid receptors were investigated on 3 different schedules of water intake in the rat: spontaneous, deprivational (12 h), and hypertonic saline-induced drinking. Peptides were injected into the paraventricular and supraoptic hypothalamic nuclei, D-Ala2-NMePhe4-Gly(ol)-enkephalin, a mu-selective opioid agonist, tended to increase water intake in non-deprived rats, but 0.01 and 0.1 microgram significantly decreased water intake for 45 min in deprived rats, and for up to 60 min in hypertonic saline-injected rats when injected into the paraventricular hypothalamic nucleus. The kappa-selective agonist, dynorphin A1-13 (0.1, 0.3, 1.0 and 3.0 micrograms)and the delta-selective agonist, [D-Pen2,L-Pen5]enkephalin (0.3 and 3.0 micrograms) did not affect spontaneous, deprivational or hypertonic saline-induced water intakes when injected into either the paraventricular or supraoptic hypothalamic nuclei. Thus, a mu-selective opioid peptide produced dose- and time-dependent effects on drinking that were pharmacologically and anatomically specific, and dependent upon the schedule of water intake.

Effects of opiate agonists and antagonists on aggressive encounters and subsequent opioid-induced analgesia, activity and feeding responses in male mice

The effects of peripheral administration of the mu, kappa and sigma opiate agonists, levorphanol (1.0 mg/kg), U-50,488 (1.0 and 10.0 mg/kg), (+/-) SKF-10,047 (10.0 and 30.0 mg/kg), respectively, as well as the delta opiate antagonists, ICI-154,129 (10.0 mg/kg), and the prototypic antagonist, naloxone (1.0 mg/kg), on the agonistic behaviors and subsequent analgesic, locomotory and ingestive responses of subordinate mice were examined in a "resident-intruder" paradigm. The latter behaviors were examined in both defeated and nondefeated mice that had received an equivalent level of aggression. The mu and delta opiate antagonists decreased, while the mu, kappa, and sigma opiate agonists selectively increased aggressive behavior (number of bouts of aggressive interactions, number of bites to defeat, time to defeat). Both naloxone and the delta antagonist suppressed defeat- and aggression-induced activity and feeding, while only naloxone blocked the analgesic response. Levorphanol enhanced, U-50,488 had variable dose related effects, and SKF-10,047 decreased the defeat and aggressive-induced responses. These results indicate that various opioid systems and opiate receptors are differentially involved in the mediation of various components of the agonistic encounters and in the expression of the consequences of social conflict and defeat-induced opioid activation.

Apomorphine markedly potentiates naltrexone-induced hypodipsia in the rat

This article describes the effects of apomorphine on naltrexone-induced decreases in water intake of the rat deprived of water for 24 h. Apomorphine alone at reasonable doses (0.03, 0.1, 0.3 and 1.0 mg/kg) failed to affect water intake of the rat, but a higher dose (3.0 mg/kg) abolished water intake completely, accompanied by marked stereotypy. Naltrexone (0.1, 1.0 and 10.0 mg/kg) produced a dose-dependent reduction in water intake. A 0.3-mg/kg dose of apomorphine which is considered to activate preferentially presynaptic dopamine autoreceptors enhanced markedly naltrexone (1.0 and 10.0 mg/kg)-induced decreases in water intake. Only apomorphine at 1.0 mg/kg caused a significant prolongation of the latency to start drinking. Apomorphine (0.3 mg/kg), naltrexone (0.1, 1.0 and 10.0 mg/kg) or their combinations did not produce a marked effect on locomotor activity in the rat. These results suggest that apomorphine is capable of potentiating naltrexone-induced decreases in water intake through the mediation of presynaptic dopamine autoreceptors without causing motor dysfunction.

Involvement of mu opioid receptors in the amygdala in the control of feeding

The intake of food by rats was measured after unilateral injections of opioid peptides into or near the central nucleus of the amygdala. The selective mu receptor agonist Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAGO) caused an increase in intake of food at doses of 1 and 3 nmol. Injections into the amygdala of [D-Ser2,Leu5]enkephalin-Thr6 (DSLET), a selective delta agonist, and dynorphin A, a selective kappa agonist, were ineffective at doses up to 3 nmol. However, dynorphin (2 nmol) did increase intake when injected into the medial hypothalamus. Bilateral injections of DAGO into the amygdala were no more effective than unilateral injections. The effect of DAGO was blocked by injections into the amygdala of naloxone or beta-chlornaltrexamine, an ultralong-lasting opioid receptor antagonist. These studies suggest that mu opioid receptors in the amygdala contribute to the regulation of intake of food. A role for kappa and delta receptors was not established but cannot be ruled out without further testing.

Effect of chronic intracerebroventricular morphine to feeding responses in male rats

Stainless steel cannulae were implanted stereotaxically in the third ventricle of male albino rats. The rats were fed with natural food pellets and water ad lib. After seven days of cannulation, daily body weight, food intake and water intake were recorded for the first five days, which was considered the preinjection control. Then increased and repetitive injections of morphine sulphate were administered intracerebroventricularly (ICV) in dosage of 30 micrograms/2 microliter, 45 micrograms/3 microliter, 60 micrograms/4 microliter, 75 micrograms/5 microliter, 90 micrograms/6 microliter and 105 micrograms/7 microliter on each following day respectively. In a separate set of experiments, the blood glucose levels were measured in animals injected with morphine to a dose corresponding to 15 micrograms/1 microliter, 30 micrograms/2 microliter, 45 micrograms/3 microliter, 60 micrograms/4 microliter and 75 micrograms/5 microliter on days 1, 2, 3, 4 and 5 respectively. Statistically significant (p less than 0.001) decreases in the body weight, food intake, water intake and increase in blood glucose were observed. The inferences derived from the above observations for the possible involvement and interaction of opioids in the regulation of feeding mechanisms have been discussed.

Involvement of kappa type opioids on ethanol drinking

The effects of the administration of the kappa agonist dynorphin1-17 and/or the kappa antagonist MR-2266-BS on ethanol preference was investigated using a paradigm by which rats develop alcohol preference. Administration of dynorphin shortly before or after the conditioning session (forced ethanol exposure) failed to affect later ethanol preference. However, dynorphin treatment prior to the first choice session reduced ethanol preference during the three consecutive testing days. This effect was reversed by the simultaneous administration of the kappa antagonist MR-2266-BS. The results of the present study provide further support for evidence of the involvement of dynorphinergic systems on drinking behavior and suggest that kappa-type opioid mechanisms may be involved in the consumption and development of preference to ethanol in rats.

Decreased [3H]-naloxone binding and elevated dynorphin-A(1-8) content in Zucker rat brain

We have previously reported that female obese Zucker rats are hypersensitive to painful stimuli and are resistant to the analgesic effects of morphine. In continuation we hypothesized that these phenomena are possibly the result of diminished population of opioid receptors, or an overabundance of dynorphin interfering with morphine analgesia. We now report that female obese Zucker rats have decreased concentrations of mu opioid receptors in whole brain and elevated levels of Dynorphin A(1-8) (DYN) in a brain area known to be associated with responses to nociceptive stimuli.

An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice

This study compared the effects of chronic administration of anorexigenic drugs on weight loss in mice. Tolerance to the effects of peripheral anorexigenic peptides, viz. cholecystokinin-octapeptide and bombesin, developed rapidly. Morphine, cocaine and dehydroepiandrosterone-sulfate caused weight loss and appeared similar to d-amphetamine in mechanisms of action. A high dose of fluoxetine (25 mg/kg) proved to be a potent leptogenic agent but was also associated with death in some animals. A lower dose of fluoxetine (5 mg/kg) was associated with the development of tolerance. Calcitonin, a potent anorexigenic agent, did not produce weight loss and tolerance to its anorectic effect had developed by 10 days. Animals varied widely in their individual responsiveness to a given drug. Peripheral administration of peptide YY caused weight loss. We conclude that acute or chronic effects of agents on food intake do not necessarily predict effects on body weight. However, neurotransmitters that enhance feeding centrally appear to cause weight loss when administered peripherally.

Effects of beta-chlornaltrexamine on food intake, body weight and opioid-induced feeding

beta-Chlornaltrexamine (beta-CNA) is a non-equilibrium opioid receptor antagonist which alkylates and inactivates opioid receptors. Because opioid peptides are thought to contribute to the regulation of food intake, we examined the effects of intracerebroventricular (icv) injections of beta-CNA on the food intake and body weight of male rats. We also tested the ability of beta-CNA to block food intake stimulated by selective agonists of kappa, mu and delta opioid receptors: dynorphin A2 (DYN), Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAGO), and [(D-Ser2,Leu5]-enkephalin-Thr6 (DSLET). Treatment with beta-CNA caused a long-term (2-4 days) reduction in daily food intake and a concomitant reduction in body weight. An additional experiment indicated that the weight loss after beta-CNA treatment could be completely accounted for by the reduction in intake. beta-CNA treatment also abolished or greatly attenuated the feeding effects of DAGO, DSLET and DYN, even when these peptides were tested 26 hours after beta-CNA administration. The long duration of the effects of beta-CNA suggests that this compound will be a useful pharmacological tool in further study of the opioid feeding system.

Suppression of deprivation-induced water intake in the rat by opioid antagonists: central sites of action

The effects of naltrexone methobromide, a quaternary derivative of the opioid antagonist naltrexone, were investigated on deprivation (24 h)-induced water intake in the unilaterally cannulated rats. Naltrexone methobromide reduced post-deprivational water intake with an ED50 of 7.3 micrograms when tested at 30 min (peak effect) after intracerebroventricular administration. It also dose-dependently (0.3-10 micrograms) depressed water intake, with peak effects at 15 min, after microinjection into the paraventricular hypothalamic nucleus and into the supraoptic hypothalamic nucleus. The drug did not produce any other effects on behaviors. The ED50S were 1.4 micrograms when given into the paraventricular nucleus, and 3.3 micrograms when given into the supraoptic nucleus, respectively. Although injections of higher doses (1.0, 3.0 and/or 10 micrograms) of the drug into the preoptic area, zona incerta, and corpus callosum significantly suppressed water intake, other behavioral manifestations, such as rotational behaviors, convulsions, body shakes, head swaying, and/or backward locomotion were manifested simultaneously with the reduction in drinking. When injected into the lateral hypothalamic area, water intake was not significantly affected by the drug. These findings suggest that the paraventricular and supraoptic hypothalamic nuclei are important sites of action in the naltrexone-induced suppression of water intake.

Opioid peptide effects on feeding in rabbits

The food intake of rabbits was measured after intracerebroventricular injections of several opioid agonists and naloxone. The preferential kappa agonist dynorphin A increased intake, while naloxone, [D-Ser2,Leu5]enkephalin-Thr6 and Tyr-D-Ala-Gly-(Me)Phe-Gly-ol reduced intake or had no effect. These results suggest that kappa receptors have a role in the control of feeding in rabbits.